Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Med Oral Patol Oral Cir Bucal ; 23(1): e7-e12, 2018 Jan 01.
Article in English | MEDLINE | ID: mdl-29274161

ABSTRACT

BACKGROUND: Lower lip squamous cell carcinoma (LLSCC) is a common malignancy of the head and neck, being mainly a consequence of a chronic exposure to ultraviolet (UV) light solar radiation. Here, we evaluated the clinicopathological profile of patients with photosensitive disorders (xeroderma pigmentosum, lupus erythematosus and albinism) that developed LLSCC. MATERIAL AND METHODS: Data from patients who had a diagnosed LLSCC with a prior xeroderma pigmentosum, lupus erythematosus or albinism diagnosis that were treated at INCA from 1999 to 2012 were collected from patients medical records (n=16). The control group was composed of 68 patients with LLSCC without a medical history of photosensitivity. The clinicopathological data of this study population were collected and the association between these variables was analyzed by Fisher's exact test. Survival curves were constructed using the Kaplan-Meier method and compared by log-rank test. All statistical analyses were performed using SPSS statistics package. RESULTS: The mean age of patients in the photosensitive and non-photosensitive groups was 42 years and 67 years, respectively (p<0.0001). A previous history of malignant diseases was more common in the photosensitive group (p=0.001). In both groups, most tumors showed a pathological stage I/II disease. Overall and cancer-specific survival were not statistically different. However, disease-free interval showed a significant difference (p=0.01) between the photosensitive and non-photosensitive patients. CONCLUSIONS: Photosensitive patients presented LLSCC at earlier age but it usually was not the primary tumor in these patients. Furthermore, a more aggressive pathological behavior was not seen when compared with tumors from non-photosensitive patients. The disease-free interval was lower in photosensitive patients, as expected.


Subject(s)
Carcinoma, Squamous Cell/complications , Head and Neck Neoplasms/complications , Lip Neoplasms/complications , Photosensitivity Disorders/complications , Academies and Institutes , Adolescent , Adult , Aged , Brazil , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/therapy , Child , Female , Head and Neck Neoplasms/epidemiology , Head and Neck Neoplasms/therapy , Humans , Lip Neoplasms/epidemiology , Lip Neoplasms/therapy , Male , Middle Aged , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck , Time Factors , Young Adult
3.
Genet Mol Res ; 10(4): 2340-8, 2011 Oct 05.
Article in English | MEDLINE | ID: mdl-22002127

ABSTRACT

In rats, N-nitrosodiethylamine (NDEA) induces tumors mainly in the liver. This could be because various enzymes are responsible for the metabolic activation of NDEA, besides the hepatic NDEA metabolizing enzyme, CYP2E1. We examined NDEA genotoxicity and cytotoxicity in primary cultures of female rat hepatocytes; we also looked at how it affected CYP mRNA expression. Single incubation with 0.9% NaCl resulted in a mean of 0.2% apoptotic cells, which doubled with 105 µg NDEA/mL. The frequency of necrosis with NDEA treatment was also doubled. Besides the cytotoxic effects, there was also a 4-fold decrease in mitotic index and a 3-fold decrease in the percentage of cells with micronuclei. A significant increase in micronucleus cells when hepatocytes were incubated with 2.1 µg NDEA/mL suggests that DNA repair was inactive. The chromosomal aberration evaluation revealed a discrete dose-response curve. Treatment with NDEA induced increases in CYP mRNA: CYP2B2 (1.8 times) and CYP2E1 (1.6 times) with non-cytotoxic NDEA concentrations (0.21-21 µg/mL). CYP2B1 mRNA levels decreased at 0.21 µg NDEA/mL (2.5-fold), while CYP4A3 mRNA decreased 1.3-fold. NDEA treatment at 2.1 µg/ mL induced a 1.9-fold increase in CYP3A1 mRNA. Understanding the cumulative effects in target cells during precarcinogenesis is crucial to understanding the mode of action of potential carcinogens and in order to develop comprehensive chemical toxicity profiles.


Subject(s)
Alkylating Agents/pharmacology , Aryl Hydrocarbon Hydroxylases/biosynthesis , Cytochrome P-450 CYP2E1/biosynthesis , DNA Damage/drug effects , Diethylnitrosamine/pharmacology , Gene Expression Regulation, Enzymologic/drug effects , Hepatocytes/enzymology , Steroid Hydroxylases/biosynthesis , Animals , Apoptosis/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Female , Hepatocytes/pathology , Liver Neoplasms/chemically induced , Liver Neoplasms/enzymology , Liver Neoplasms/pathology , Necrosis/enzymology , Necrosis/pathology , RNA, Messenger , Rats , Rats, Inbred F344
4.
Food Chem Toxicol ; 46(3): 1190-5, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18215451

ABSTRACT

CYP2A enzymes are responsible for nicotine metabolism and for activating tobacco-related carcinogens. Inhibition of CYP2A is a promising approach in chemoprevention, which could lead to a decrease in cigarette consumption and to a reduction in tobacco-related cancer risk. 8-Methoxypsoralen (8-MOP) is a mechanism-based inhibitor of human CYP2A6 and CYP2A13. 8-MOP is also an inhibitor of Cyp2a5, but the mode of this inhibition is unknown. There is no published data on the inhibition of CYP2A3 by 8-MOP. The objective of this work was to investigate the characteristics of 8-MOP inhibition on mouse hepatic Cyp2a5 and rat nasal CYP2A3, in order to determine the best experimental model for chemoprevention studies using 8-MOP. The results show that 8-MOP inhibits CYP2a5 through three different mechanisms: competitive, non-competitive (K(iu)=1.7 microM), and mechanism-based (K(inactivation) of 0.17 min(-1)). By contrast, 8-MOP was able to inhibit CYP2A3-mediated coumarin 7-hydroxylase only in a non-competitive way (K(iu)=0.22 microM). In conclusion, we showed that 8-MOP inhibits Cyp2a5 and CYP2A3 through different mechanisms.


Subject(s)
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Methoxsalen/pharmacology , Mixed Function Oxygenases/antagonists & inhibitors , Animals , Cytochrome P-450 CYP2A6 , Cytochrome P450 Family 2 , Kinetics , Male , Mice , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL